No biomarker
No biomarker
|
Gastroesophageal Junction Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
|
nivolumab
Bristol-Myers Squibb Press Release - 6 days
|
HER-2 positive
HER-2 positive
|
Gastric Cancer
Gastric Cancer
|
trastuzumab
Sensitive: A2 - Guideline
Future Oncol - 1 week
|
MTA2 expression
MTA2 expression
|
Gastric Cancer
Gastric Cancer
|
olaparib
Sensitive: D – Preclinical
Transl Oncol - 2 weeks
|
HER-2 positive
HER-2 positive
|
Gastroesophageal Junction Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
|
|
No biomarker
No biomarker
|
Gastric Cancer
Gastric Cancer
|
|
No biomarker
No biomarker
|
Gastric Adenocarcinoma
Gastric Adenocarcinoma
|
cisplatin + 5-fluorouracil + docetaxel
|
No biomarker
No biomarker
|
Gastroesophageal Junction Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
|
cisplatin + 5-fluorouracil + docetaxel
|
HER-2 positive
HER-2 positive
|
Gastric Cancer
Gastric Cancer
|
fam-trastuzumab deruxtecan-nxki
|
HER-2 positive
HER-2 positive
|
Gastroesophageal Junction Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
|
fam-trastuzumab deruxtecan-nxki
|
No biomarker
No biomarker
|
Gastric Cancer
Gastric Cancer
|
|
No biomarker
No biomarker
|
Gastroesophageal Junction Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
|
|
HER-2 positive
HER-2 positive
|
Gastric Cancer
Gastric Cancer
|
pembrolizumab + trastuzumab
|
HER-2 Negative + PD-L1 expression
HER-2 Negative + PD-L1 expression
|
Gastroesophageal Junction Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
|
|
HER-2 overexpression
HER-2 overexpression
|
Gastric Cancer
Gastric Cancer
|
|
No biomarker
No biomarker
|
Gastroesophageal Junction Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
|
|
HER-2 positive
HER-2 positive
|
Gastroesophageal Junction Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
|
Trazimera (trastuzumab biosimilar)
|
HER-2 overexpression
HER-2 overexpression
|
Gastric Cancer
Gastric Cancer
|
Trazimera (trastuzumab biosimilar)
|
HER-2 positive
HER-2 positive
|
Gastroesophageal Junction Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
|
Ontruzant (trastuzumab biosimilar)
|
HER-2 overexpression
HER-2 overexpression
|
Gastric Cancer
Gastric Cancer
|
Ontruzant (trastuzumab biosimilar)
|
HER-2 positive
HER-2 positive
|
Gastroesophageal Junction Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
|
Ogivri (trastuzumab biosimilar)
|
HER-2 overexpression
HER-2 overexpression
|
Gastric Cancer
Gastric Cancer
|
Ogivri (trastuzumab biosimilar)
|
HER-2 positive
HER-2 positive
|
Gastroesophageal Junction Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
|
Kanjinti (trastuzumab biosimilar)
|
HER-2 overexpression
HER-2 overexpression
|
Gastric Cancer
Gastric Cancer
|
Kanjinti (trastuzumab biosimilar)
|
HER-2 positive
HER-2 positive
|
Gastroesophageal Junction Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
|
Herzuma (trastuzumab biosimilar)
|
HER-2 overexpression
HER-2 overexpression
|
Gastric Cancer
Gastric Cancer
|
Herzuma (trastuzumab biosimilar)
|
No biomarker
No biomarker
|
Gastroesophageal Junction Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
|
|
No biomarker
No biomarker
|
Gastric Cancer
Gastric Cancer
|
|
No biomarker
No biomarker
|
Gastric Cancer
Gastric Cancer
|
|
No biomarker
No biomarker
|
Gastric Cancer
Gastric Cancer
|
|
No biomarker
No biomarker
|
Gastroesophageal Junction Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
|
|
HER-2 positive
HER-2 positive
|
Gastroesophageal Junction Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
|
Zercepac (trastuzumab biosimilar)
|
HER-2 overexpression
HER-2 overexpression
|
Gastroesophageal Junction Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
|
|
HER-2 overexpression
HER-2 overexpression
|
Gastric Cancer
Gastric Cancer
|
Zercepac (trastuzumab biosimilar)
|
HER-2 positive
HER-2 positive
|
Gastric Cancer
Gastric Cancer
|
Zercepac (trastuzumab biosimilar)
|
HER-2 overexpression
HER-2 overexpression
|
Gastroesophageal Junction Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
|
Ontruzant (trastuzumab biosimilar)
|
HER-2 overexpression
HER-2 overexpression
|
Gastroesophageal Junction Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
|
Kanjinti (trastuzumab biosimilar)
|
HER-2 overexpression
HER-2 overexpression
|
Gastroesophageal Junction Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
|
Ogivri (trastuzumab biosimilar)
|
HER-2 positive
HER-2 positive
|
Gastroesophageal Junction Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
|
pembrolizumab + trastuzumab
|
No biomarker
No biomarker
|
Gastroesophageal Junction Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
|
|
No biomarker
No biomarker
|
Gastric Cancer
Gastric Cancer
|
|
HER-2 negative
HER-2 negative
|
Gastric Cancer
Gastric Cancer
|
cisplatin + capecitabine
Sensitive: A2 - Guideline
|
HER-2 negative
HER-2 negative
|
Gastroesophageal Junction Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
|
cisplatin + capecitabine
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Gastroesophageal Junction Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
|
DOF
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Gastric Cancer
Gastric Cancer
|
TCF
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Gastroesophageal Junction Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
|
TCF
Sensitive: A2 - Guideline
|
PD-L1 expression
PD-L1 expression
|
Gastroesophageal Junction Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
|
pembrolizumab
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Gastroesophageal Junction Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
|
FP
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Gastroesophageal Junction Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
|
CaT
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Gastric Cancer
Gastric Cancer
|
FP
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Gastric Cancer
Gastric Cancer
|
FOLFIRI
Sensitive: A2 - Guideline
|
PD-L1 expression
PD-L1 expression
|
Gastric Cancer
Gastric Cancer
|
pembrolizumab
Sensitive: A2 - Guideline
|
HER-2 negative
HER-2 negative
|
Gastroesophageal Junction Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
|
CAPOX
Sensitive: A2 - Guideline
|
HER-2 negative
HER-2 negative
|
Gastroesophageal Junction Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
|
5-fluorouracil + oxaliplatin
Sensitive: A2 - Guideline
|
HER-2 negative
HER-2 negative
|
Gastroesophageal Junction Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
|
FP
Sensitive: A2 - Guideline
|
HER-2 Negative + PD-L1 expression
HER-2 Negative + PD-L1 expression
|
Gastroesophageal Junction Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
|
nivolumab
Sensitive: A2 - Guideline
|
HER-2 Negative + PD-L1 expression
HER-2 Negative + PD-L1 expression
|
Gastric Cancer
Gastric Cancer
|
nivolumab
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Gastroesophageal Junction Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
|
capecitabine
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Gastroesophageal Junction Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
|
5-fluorouracil
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Gastroesophageal Junction Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
|
DP
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Gastric Cancer
Gastric Cancer
|
5-fluorouracil
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Gastric Cancer
Gastric Cancer
|
5-fluorouracil + irinotecan
Sensitive: A2 - Guideline
|
HER-2 negative
HER-2 negative
|
Gastric Cancer
Gastric Cancer
|
cisplatin + 5-fluorouracil
Sensitive: A2 - Guideline
|
HER-2 negative
HER-2 negative
|
Gastric Cancer
Gastric Cancer
|
CAPOX
Sensitive: A2 - Guideline
|
HER-2 negative
HER-2 negative
|
Gastric Cancer
Gastric Cancer
|
5-fluorouracil + oxaliplatin
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Gastric Cancer
Gastric Cancer
|
paclitaxel + 5-fluorouracil
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Gastric Cancer
Gastric Cancer
|
paclitaxel + capecitabine
Sensitive: A2 - Guideline
|
|
Gastric Cancer
Gastric Cancer
|
pembrolizumab
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Gastric Cancer
Gastric Cancer
|
FLOT
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Gastroesophageal Junction Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
|
FLOT
Sensitive: A2 - Guideline
|
HER-2 positive
HER-2 positive
|
GastroEsophageal Cancer
GastroEsophageal Cancer
|
trastuzumab
Sensitive: A2 - Guideline
|
PD-L1 expression
PD-L1 expression
|
Gastric Adenocarcinoma
Gastric Adenocarcinoma
|
pembrolizumab
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Gastric Cancer
Gastric Cancer
|
cisplatin + irinotecan
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Gastric Cancer
Gastric Cancer
|
irinotecan
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Gastric Cancer
Gastric Cancer
|
paclitaxel
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Gastric Cancer
Gastric Cancer
|
docetaxel
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Gastric Cancer
Gastric Cancer
|
docetaxel + irinotecan
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Gastric Cancer
Gastric Cancer
|
cisplatin + docetaxel
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Gastric Cancer
Gastric Cancer
|
carboplatin + paclitaxel
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Gastric Cancer
Gastric Cancer
|
CAPOX
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Gastric Cancer
Gastric Cancer
|
5-fluorouracil + oxaliplatin
Sensitive: A2 - Guideline
|
|
Gastroesophageal Junction Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
|
pembrolizumab
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Gastroesophageal Junction Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
|
cisplatin + capecitabine
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Gastroesophageal Junction Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
|
5-fluorouracil + irinotecan
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Gastroesophageal Junction Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
|
irinotecan
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Gastroesophageal Junction Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
|
paclitaxel
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Gastroesophageal Junction Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
|
docetaxel
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Gastroesophageal Junction Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
|
docetaxel + irinotecan
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Gastroesophageal Junction Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
|
IP
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Gastroesophageal Junction Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
|
5-fluorouracil + oxaliplatin
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Gastroesophageal Junction Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
|
capecitabine + oxaliplatin
Sensitive: A2 - Guideline
|
NTRK3 fusion
NTRK3 fusion
|
Gastroesophageal Junction Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
|
larotrectinib
Sensitive: A2 - Guideline
|
NTRK2 fusion
NTRK2 fusion
|
Gastroesophageal Junction Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
|
larotrectinib
Sensitive: A2 - Guideline
|
NTRK1 fusion
NTRK1 fusion
|
Gastroesophageal Junction Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
|
larotrectinib
Sensitive: A2 - Guideline
|
NTRK3 fusion
NTRK3 fusion
|
Gastroesophageal Junction Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
|
entrectinib
Sensitive: A2 - Guideline
|
NTRK2 fusion
NTRK2 fusion
|
Gastroesophageal Junction Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
|
entrectinib
Sensitive: A2 - Guideline
|
